The role of infectious agents in urogenital cancers

Infectious Agents and Cancer

Ildar Bekniyazov²  Nargis Karatayeva²  Kenneth Alibek¹ 

[1] Republican Scientific Center for Emergency Care, 3 Kerey and Zhanibek Khan Street, Astana 010000, Kazakhstan;Nazarbayev University, 53 Kabanbay Batyr Avenue, Astana 010000, Kazakhstan

关键词: Human polyomaviruses;    CMV;    Epstein-Barr;    HPV;    Schistosoma haematobium;    Mycoplasma genitalium;    Neisseria gonorrhea;    Chlamydia trachomatis;    Kidney cancer;    Bladder cancer;    Cervical cancer;    Ovarian cancer;    Urogenital cancers;   

Others  :  803303
DOI  :  10.1186/1750-9378-7-35

 received in 2012-05-21, accepted in 2012-11-20,  发布年份 2012

【 摘 要 】

Since the late 1990s, infectious agents have been thought to play a role in the pathogenesis of approximately 15% of cancers. It is now widely accepted that infection of stomach tissue with the bacteria Helicobacter pylori is an important cause of stomach adenocarcinoma. In addition, oncogenic viruses, such as papilloma viruses, herpes viruses, and hepadnaviruses are strongly associated with increased risk of cervical cancer, lymphomas, liver cancer, amongst others. However, in the scientific community the percentage of cancers caused by pathogens is believed to be far higher than 15%. A significant volume of data collected to date show an association between infectious agents and urogenital cancers. These agents include Chlamydia trachomatis, Neisseria gonorrhoea, Mycoplasma genitalium and certain viruses that have been implicated in ovarian cancer. Other pathogens include the hepatitis C and Epstein-Barr viruses, which are potentially involved in kidney cancer. In addition, infections with Schistosoma haematobium, the human papillomavirus, and human polyomaviruses are strongly associated with an increased risk of urinary bladder cancer. This article reviews publications available to date on the role of infectious agents in urogenital cancers. A greater understanding of the role of such agents could aid the identification of novel methods of urogenital cancer treatment.

【 授权许可】

   
2012 Alibek et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Pisani P, Parkin DM, Muñoz N, Ferlay J: Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 1997, 6(6):387-400.
• [2]Sankaranarayanan R, Ferlay J: Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 2006, 20(2):207-225.
• [3]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
• [4]Weinberg RA: The rational treatment of cancer. In The biology of cancer. 1st edition. Edited by Garland Science. LLC: Taylor & Francis Group; 2007:725-795.
• [5]Piek JM, van Diest PJ, Verheijen RH: Ovarian carcinogenesis: an alternative hypothesis. Adv Exp Med Bio 2008, 622:79-87.
• [6]Riman T, Nilsson S, Persson IR: Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand 2004, 83(9):783-795.
• [7]Lukanova A, Kaaks R: Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev 2005, 14(1):98-107.
• [8]Ness RB, Cottreau C: Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999, 91(17):1459-1467. Review. PubMed PMID: 10469746
• [9]Camargo MC, Stayner LT, Straif K, Reina M, Al-Alem U, Demers PA, Landrigan PJ: Occupational exposure to asbestos and ovarian cancer: a meta-analysis. Environ Health Perspect 2011, 119(9):1211-1217. Epub 2011 Jun 3
• [10]Reid A, de Klerk N, Musk AW: Does exposure to asbestos cause ovarian cancer? A systematic literature review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2011, 20(7):1287-1295. Epub 2011 May 24
• [11]Munksgaard PS, Blaakaer J: The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol Oncol 2012, 124(1):164-169. Epub 2011 Oct 26
• [12]Sainz de la Cuesta R, Eichhorn JH, Rice LW, Fuller AF Jr, Mikrui N, Goff BA: Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol 1996, 60:238-244.
• [13]Jimbo H, Yoshikawa H, Onda T, Yasugi T, Sakamoto A, Taketani Y: Prevalence of ovarian endometriosis in epithelial ovarian cancer. Int J Gynecol Obstet 1997, 59:245-250.
• [14]DePriest PD, Banks ER, Powell DE, van Nagell JR, Gallion Jr HH, Puls SE: Endometrioid carcinoma of the ovary and endometriosis: the association in postmenopausal women. Gynecol Oncol 1992, 47:71-75.
• [15]Rice MS, Murphy MA, Tworoger SS: Tubal ligation, hysterectomy and ovarian cancer: a meta-analysis. J Ovarian Res. 2012, 5(1):13. BioMed Central Full Text
• [16]Shu XO, Brinton LA, Gao YT, Yuan JM: Population-based case–control study of ovarian cancer in Shanghai. Cancer Res 1989, 49:3670-3674.
• [17]Risch HA, Howe GR: Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 1995, 4:447-451.
• [18]Rakoff-Nahoum S: Why cancer and inflammation? Yale J Biol Med 2006, 79(3–4):123-130.
• [19]Hussain SP, Hofseth LJ, Harris CC: Radical causes of cancer. Nat Rev Cancer 2003, 3(4):276-285.
• [20]Greene W, Xiao Y, Huang Y, McClarty G, Zhong G: Chlamydia-infected cells continue to undergo mitosis and resist induction of apoptosis. Infect Immun 2004, 72(1):451-460.
• [21]IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007, 90:1-636.
• [22]Paavonen J: Chlamydia trachomatis and cancer. Sex Transm Infect 2001, 77:154-156.
• [23]Idahl A, Lundin E, Jurstrand M, Kumlin U, Elgh F, Ohlson N, Ottander U: Chlamydia trachomatis and mycoplasma genitalium plasma antibodies in relation to epithelial ovarian tumors. Infect Dis Obstet Gynecol 2011, 2011:824627. Published online 2011 July 28
• [24]Goering RV: Sexually transmitted diseases. In Mims’ Medical Microbiology. 1st edition. Edited by Goering R, Dockrell H, Roitt I, Zuckerman M, Wakelin D. Elsevier Limited; 2003:261-285.
• [25]Scidmore MA, Fischer ER, Hackstadt T: Restricted fusion of Chlamydia trachomatis vesicles with endocytic compartments during the initial stages of infection. Infect Immun 2003, 71(2):973-984.
• [26]Zhong GM, Reid RE, Brunham RC: Mapping antigenic sites on the major outer membrane protein of Chlamydia trachomatis with synthetic peptides. Infect Immun 1990, 58(5):1450-1455.
• [27]Zhong G, Fan T, Liu L: Chlamydia inhibits interferon gamma-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1. J Exp Med 1999, 189(12):1931-1938.
• [28]Zhong G, Liu L, Fan T, Fan P, Ji H: Degradation of transcription factor RFX5 during the inhibition of both constitutive and interferon gamma-inducible major histocompatibility complex class I expression in chlamydia-infected cells. J Exp Med 2000, 191(9):1525-1534.
• [29]Zhong G, Fan P, Ji H, Dong F, Huang Y: Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors. J Exp Med 2001, 193(8):935-942.
• [30]Dean D, Powers VC: Persistent Chlamydia trachomatis infections resist apoptotic stimuli. Infect Immun 2001, 69(4):2442-2447.
• [31]Beatty WL, Byrne GI, Morrison RP: Morphologic and antigenic characterization of interferon gamma-mediated persistent Chlamydia trachomatis infection in vitro. Proc Natl Acad Sci USA 1993, 90(9):3998-4002.
• [32]Hjelholt A, Christiansen G, Johannesson TG, Ingerslev HJ, Birkelund S: Tubal factor infertilityis associated with antibodies against Chlamydia trachomatis heat shock protein 60 (HSP60) but not human HSP60. Hum Reprod 2011, 26(8):2069-2076.
• [33]Cooper MD, Rapp J, Jeffery-Wiseman C, Barnes RC, Stephens DS: Chlamydia trachomatis infection of human fallopian tube organ cultures. J Gen Microbiol 1990, 136(6):1109-1115.
• [34]Belland RJ, Scidmore MA, Crane DD, Hogan DM, Whitmire W, McClarty G, Caldwell HD: Chlamydia trachomatis cytotoxicity associated with complete and partial cytotoxin genes. Proc Natl Acad Sci USA 2001, 98(24):13984-13989.
• [35]Baczynska A, Funch P, Fedder J, Knudsen HJ, Birkelund S, Christiansen G: Morphology of human Fallopian tubes after infection with Mycoplasma genitalium and Mycoplasma hominis–in vitro organ culture study. Hum Reprod 2007, 22(4):968-979.
• [36]Jazaeri AA, Bryant JL, Park H, Li H, Dahiya N, Stoler MH, Ferriss JS, Dutta A: Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia 2011, 13(10):899-911.
• [37]Namiki K, Goodison S, Porvasnik S, Allan RW, Iczkowski KA, Urbanek C, Reyes L, Sakamoto N, Rosser CJ: Persistent exposure to Mycoplasma induces malignant transformation of human prostate cells. PLoS One 2009, 4(9):e6872.
• [38]Jones A, Jonsson AB, Aro H: Neisseria gonorrhoeae infection causes a G1 arrest in human epithelial cells. FASEB J 2007, 21(2):345-355.
• [39]Löfmark S, de Klerk N, Aro H: Neisseria gonorrhoeae infection induces altered amphiregulin processing and release. PLoS One 2011, 6(1):e16369.
• [40]Busser B, Sancey L, Brambilla E, Coll JL, Hurbin A: The multiple roles of amphiregulin in human cancer. Biochim Biophys Acta 2011, 1816(2):119-131.
• [41]Shanmughapriya S, Senthilkumar G, Vinodhini K, Das BC, Vasanthi N, Natarajaseenivasan K: Viral and bacterial aetiologies of epithelial ovarian cancer. Eur J Clin Microbiol Infect Dis 2012. [Epub ahead of print]
• [42]Michaelis M, Doerr HW, Cinatl J Jr: The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia 2009, 11(1):1-9.
• [43]HPV and cancer National Cancer Institute 2012. [online] Available at: http://www.cancer.gov/cancertopics/factsheet/Risk/HPV#r5 webcite [Accessed 17 September 2012]
• [44]Lehtinen M, Ault KA, Lyytikainen E, Dillner J, Garland SM, Ferris DG, Koutsky LA, Sings HL, Lu S, Haupt RM, Paavonen J, FUTURE I and II Study Group: Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect 2011, 87(5):372-376.
• [45]Sasagawa T, Shimakage M, Nakamura M, Sakaike J, Ishikawa H, Inoue M: Epstein-Barr virus (EBV) genes expression in cervical intraepithelial neoplasia and invasive cervical cancer: a comparative study with human papillomavirus (HPV) infection. Hum Pathol 2000, 31(3):318-326.
• [46]Shimakage M, Sasagawa T: Detection of Epstein–Barr virus-determined nuclear antigen-2 mRNA by in situ hybridization. J Virol Methods 2001, 93(1–2):23-32.
• [47]Shimakage M, Harada S, Kawahara K: Detection of Epstein-Barr Virus Nuclear Antigen Leader Protein Expression in Various Human Cancers. In New Developments in Epstein-Barr Virus Research Chapter XI. Edited by Umar CS. Nova Science Publishers; 2006:261-276.
• [48]Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR, Rush BB, Lawler P, Sherman ME: Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994, 169(2):235-240.
• [49]Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, Sherman ME, Wacholder S, Tarone R, Burk RD: A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005, 191(11):1808-1816.
• [50]Samoff E, Koumans EH, Markowitz LE, Sternberg M, Sawyer MK, Swan D, Papp JR, Black CM, Unger ER: Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. Am J Epidemiol 2005, 162(7):668-675.
• [51]Shew ML, Fortenberry JD, Tu W, Juliar BE, Batteiger BE, Qadadri B, Brown DR: Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med 2006, 160(2):151-156.
• [52]Szkaradkiewicz A, Wal M, Kuch A, Pieta P: Human papillomavirus (HPV) and Epstein-Barr virus (EBV) cervical infections in women with normal and abnormal cytology. Pol J Microbiol 2004, 53(2):95-99.
• [53]Gordon SC, Moonka D, Brown KA, Rogers C, Huang MA, Bhatt N, Lamerato L: Risk for renal cell carcinoma in chronic hepatitis C infection. Cancer Epidemiol Biomarkers Prev 2010, 19(4):1066-1073.
• [54]Salehipoor M, Khezri A, Behzad-Behbahani A, Geramizadeh B, Rahsaz M, Aghdaei M, Afrasiabi MA: Role of viruses in renal cell carcinoma. Saudi J Kidney Dis Transpl 2012, 23(1):53-57.
• [55]Shimakage M, Kawahara K, Harada S, Sasagawa T, Shinka T, Oka T: Expression of Epstein-Barr virus in renal cell carcinoma. Oncol Rep 2007, 18:41-46.
• [56]Parker A, Cerhan J, Lynch C, Leibovich B, Cantor K: History of urinary tract infection and risk of renal cell carcinoma. Am J Epidemiol 2004, 159:42-48.
• [57]American Cancer Society: Global Cancer Facts & Figures. 2nd edition. Atlanta: American Cancer Society; 2011.
• [58]Fried B, Reddy A, Mayer D: Helminthes in human carcinogenesis. Cancer Lett 2011, 305:239-249.
• [59]IARC: Monograph on the evaluation of carcinogenic risks to humans: schistosomes, liver flukes and Helicobacter pylori. Volume 61. WHO: International Agency for Research on Cancer; 1994:9-175.
• [60]Bedwani R, Renganathan E, El Kwhsky F, Braga C, Abu Seif HH, Abul Azm T, Zaki A, Franceschi S, Boffetta P, La Vecchia C: Schistosomiasis and the risk of bladder cancer in Alexandria, Egypt. Br J Cancer 1998, 77(7):1186-1189.
• [61]Li N, Yang L, Zhang Y, Zhao P, Zheng T, Dai M: Human papillomavirus infection and bladder cancer risk: a meta-analysis. J Infect Dis 2011, 204(2):217-223.
• [62]Del Mistro A, Koss LG, Braunstein J, Bennett B, Saccomano G, Simons KM: Condyloma acuminata of the urinary bladder. Natural history, viral typing, and DNA content. Am J Surg Pathol 1988, 12(3):205-215.
• [63]Kitamura T, Yogo Y, Ueki T, Murakami S, Aso Y: Presence of human papillomavirus type 16 genome in bladder carcinoma in situ of a patient with mild immunodeficiency. Cancer Res 1988, 48(24 Pt 1):7207-7211.
• [64]Querci della Rovere G, Oliver RT, McCance DJ, Castro JE: Development of bladder tumor containing HPV type 11 DNA after renal transplantation. Br J Urol 1988, 62(1):36-38.
• [65]Maloney KE, Wiener JS, Walther PJ: Oncogenic human papillomaviruses are rarely associated with squamous cell carcinoma of the bladder: evaluation by differential polymerase chain reaction. J Urol 1994, 151(2):360-364.
• [66]Barghi MR, Hajimohammadmehdiarbab A, Moghaddam SM, Kazemi B: Correlation between human papillomavirus infection and bladder transitional cell carcinoma. BMC Infect Dis 2005, 5:102. BioMed Central Full Text
• [67]Moonen PM, Bakkers JM, Kiemeney LA, Schalken JA, Melchers WJ, Witjes JA: Human papillomavirus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol 2008, 53(4):858-859.
• [68]Frank GA, Zavalishina LE, Andreeva l: Immunohistochemical characteristics and a degree of differentiation of urinary bladder cancer. Arkh Patol 2002, 64(6):16-18.
• [69]Volgareva G, Trofimova O, Kuevda D, Zavalishina L, Golovina D, Andreeva Y, Ermilova V, Cheban N, Glazunova V, Matvejev V, Shipulina O, Frank G: HPV and urinary bladder cancer. Proceedings of the 25-th International Papillomavirus Conference. Malmo, Sweden; 2009:P-18.42.
• [70]Knöll A, Stoehr R, Jilg W, Hartmann A: Low frequency of human polyomavirus BKV and JCV DNA in urothelial carcinomas of the renal pelvis and renal cell carcinomas. Oncol Rep 2003, 10(2):487-491.
• [71]Abend JR, Jiang M, Imperiale MJ: BK virus and human cancer: innocent until proven guilty. Semin Cancer Biol 2009, 19(4):252-260.
• [72]Shen C, Wu J, Hsu C, Jou Y, Lin C, Wang M, Wu S, Chan M, Chiang M, Fang C, Chang D: The high incidence of JC virus infection in urothelial carcinoma tissue in Taiwan. J Med Virol 2011, 83(12):2191-2199.
• [73]Geetha D, Tong BC, Racusen L, Markowitz JS, Westra WH: Bladder carcinoma in a transplant recipient: evidence to implicate the BK human polyomavirus as a causal transforming agent. Transplantation 2002, 73(12):1933-1936.